Stockscreener 앱 받기
10.44
3.96%
-0.43
시장 영업 전:
10.27
-0.17
-1.63%
전일 마감가:
$10.87
열려 있는:
$10.85
하루 거래량:
16,534
Relative Volume:
0.06
시가총액:
$52.01M
수익:
-
순이익/손실:
$-12.49M
주가수익비율:
-3.5213
EPS:
-2.9648
순현금흐름:
$-5.93M
1주 성능:
+0.87%
1개월 성능:
-4.66%
6개월 성능:
-6.45%
1년 성능:
+47.04%
1일 변동 폭
$10.40
$10.85
1주일 범위
$10.04
$11.21
52주 변동 폭
$6.80
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
명칭
Mink Therapeutics Inc
전화
212-994-8250
주소
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
10.44 | 54.15M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications - Investing News Network
MiNK Therapeutics Reports Promising Results from Phase 2 Trial of agenT-797 and N-803 Combination Therapy for Coccidioides immitis Infection - Quiver Quantitative
MiNK Therapeutics Reports New Data on agenT-797, an - GlobeNewswire
MiNK outlines 90-patient randomized phase II ARDS trial with initial data expected in 2H 2026 - MSN
(INKT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co. - Moomoo
We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate - Yahoo Finance
INKT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $35 - GuruFocus
User | bigspringherald.comMiNK Therapeutics, Inc.Common Stock (Nasdaq:INKT) Stock Quote - FinancialContent
About Us - FinancialContent
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2026 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics starts phase 2 trial for lung injury therapy - Investing.com UK
Mink Therapeutics’ Earnings Call: High Promise, Tight Runway - TipRanks
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q1 2026 Earnings Conference - Moomoo
Mink Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MiNK Therapeutics (INKT) Q1 2026 loss, cash burn and going concern outlook - Stock Titan
MiNK (INKT) Q4 2025 Earnings Call Transcript - The Globe and Mail
MiNK (INKT) Q1 2026 Earnings Call Transcript - The Globe and Mail
MiNK Therapeutics Initiates Phase 2 Trial for agenT-797 in Acute Lung Injury, Reports Q1 2026 Results and Advances iNKT Cell Therapy Platform - Minichart
MiNK Therapeutics Q1 Earnings Call Highlights - MarketBeat
INKT: Initiated pivotal ARDS trial with strong cash position and expanding clinical data in cancer and lung injury - TradingView
Earnings call transcript: MiNK Therapeutics Q1 2026 shows strategic progress - Investing.com
Earnings call transcript: MiNK Therapeutics Q1 2026 shows strategic progress By Investing.com - Investing.com Canada
Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call - Benzinga
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation - Investing News Network
MiNK Therapeutics starts phase 2 trial for lung injury therapy By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
MiNK Therapeutics (NASDAQ: INKT) posts Q1 loss and advances Phase 2 lung trial - Stock Titan
MINK THERAPEUTICS ($INKT) Releases Q1 2026 Earnings - Quiver Quantitative
INKT: Advanced iNKT cell therapy into Phase 2 trial, expanded platform, and improved financial position - TradingView
MiNK Therapeutics' Q1 net loss narrows slightly - TradingView
Off-the-shelf cell therapy enters ICU trial for often fatal lung failure - Stock Titan
BRIEF-MiNK Therapeutics Q1 EPS USD -0.57 - TradingView
Press Release: MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances INKT Cell Therapy Platform Into Randomized Clinical Validation - Moomoo
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness - Investing News Network
MiNK Therapeutics and First Lviv Territorial Medical Union initiate randomized phase 2 trial of agent-797 in acute lung injury and critical illness - marketscreener.com
MiNK tests immune cell therapy to help ICU patients breathe - Stock Titan
Mink Therapeutics Inc expected to post a loss of 77 cents a shareEarnings Preview - TradingView
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 - Investing News Network
MiNK Therapeutics shows iNKT cell therapy agenT... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
MiNK presents data on iNKT cell therapy agenT-797 at ASGCT By Investing.com - Investing.com South Africa
MiNK presents data on iNKT cell therapy agenT-797 at ASGCT - Investing.com
MiNK Therapeutics Presents Clinical Evidence That a Single, - GlobeNewswire
One off-the-shelf cell triggers tumor attack and calms lung injury - Stock Titan
TradingKey - TradingKey
How MiNK Therapeutics (INKT) earnings power stacks up historically | Q4 2025: Profit SurprisesAnnual Summary - newser.com
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs - The Manila Times
MiNK Therapeutics, Inc. (INKT) plans to release its financial results for the first quarter of 2026 - Bitget
Mink Therapeutics Inc (INKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):